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Background: There is a debate about the cost-efficiency of methotrexate for the management of ectopic
pregnancy (EP), especially for patients presenting with serum human chorionic gonadotrophin levels of >1500 IU/L.
We hypothesised that further experience with methotrexate, and increased use of guideline-based protocols, has
reduced the direct costs of management with methotrexate.
Methods: We conducted a retrospective cost analysis on women treated for EP in a large UK teaching hospital to
(1) investigate whether the cost of medical management is less expensive than surgical management for those
patients eligible for both treatments and (2) to compare the cost of medical management for women with hCG
concentrations 1500–3000 IU/L against those with similar hCG concentrations that elected for surgery. Three
distinct treatment groups were identified: (1) those who had initial medical management with methotrexate,
(2) those who were eligible for initial medical management but chose surgery (‘elected’ surgery) and (3) those who
initially ‘required’ surgery and did not meet the eligibility criteria for methotrexate. We calculated the costs from the
point of view of the National Health Service (NHS) in the UK. We summarised the cost per study group using the
mean, standard deviation, median and range and, to account for the skewed nature of the data, we calculated 95%
confidence intervals for differential costs using the nonparametric bootstrap method.
Results: Methotrexate was £1179 (CI 819–1550) per patient cheaper than surgery but there were no significant
savings with methotrexate in women with hCG >1500 IU/L due to treatment failures.
Conclusions: Our data support an ongoing unmet economic need for better medical treatments for EP with
hCG >1500 IU/L.
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Ectopic pregnancy is a common cause of morbidity
and occasional mortality in women of reproductive age
[1]. It is managed expectantly, medically (with metho-
trexate) or surgically. Medical management of ectopic
pregnancy is generally considered to be less expensive
than surgery [2-5].* Correspondence: andrew.horne@ed.ac.uk
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reproduction in any medium, provided the orExpectant management is a conservative strategy that
involves careful monitoring and assessment to establish
whether the ectopic pregnancy will continue to resolve
without the need for intervention. This conservative ap-
proach can only be used if the patient is stable, asymptom-
atic, at low risk of rupture and has decreasing serum
human chorionic gonadotrophin (hCG) concentrations [6].
Medical management of ectopic pregnancy may be
offered to patients with minimal symptoms, who are
haemodynamically stable, have no more than a moderate
amount of intra-abdominal free fluid on ultrasound scan
and have an hCG concentration <3000 IU/L [6]. Medicall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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methotrexate, usually in a single dose. After receiving
methotrexate, patients require close monitoring until their
serum hCG drops below 5 IU/l [7]. Around 15-20% of
women receiving a single dose of methotrexate will require
a repeat dose of this chemotherapeutic agent [7].
Surgical management is indicated if the patient is not eli-
gible for methotrexate or has symptoms or signs of tubal
rupture. This usually involves a salpingectomy but a salpin-
gotomy can be used, particularly when there is not a
healthy contralateral tube, in an attempt to preserve fertil-
ity [6]. In the absence of acute haemodynamic compromise
a laparoscopic approach is preferable to an open approach
and has been shown to be considerably cheaper [5,8].
Although there have been many studies evaluating the
efficacy of the above management options, there are only
a small number of studies that have evaluated the cost of
treating ectopic pregnancy. Studies from the USA,
Canada, New Zealand and France concluded that metho-
trexate had the potential to lead to significant savings if
used as an alternative to laparoscopic surgery [2-4].
However, it has been suggested that management with
methotrexate is only cheaper than laparoscopic surgery
when used for the treatment of patients with serum hCG
concentrations <1500 IU/l [2,5].
We hypothesised that further clinical experience with
methotrexate, and the increasing use of guideline-based
protocols, has reduced the cost of medical management.
Using data from a large UK teaching hospital, we examined
(1) whether the cost of medical management of ectopic
pregnancy remained overall less expensive than surgical
management for those patients that elected for surgery
(despite being eligible for methotrexate) and (2) compared
the cost of medical management for women with hCG
concentrations 1500–3000 IU/L against those with similar
hCG concentrations that elected for surgery.
Methods
Ethical approval
The study was discussed with the chair of Scotland A
Research Ethics Committee and we were advised that no
ethical approval was required for this project because it
was seen as service evaluation, not research.
Study population and data collected
We conducted a retrospective analysis on all women
treated either medically or surgically for tubal ectopic
pregnancy at the RIE between January 2010 and February
2011. Women managed expectantly or where the diagno-
sis was not clear were excluded. All women had com-
pleted their treatment at least one month prior to data
collection. Management criteria and eligibility for metho-
trexate followed national UK guidelines and was strictly
assessed as part of an Integrated Care Pathway [5]. Allwomen suitable for methotrexate were offered metho-
trexate or the possibility of laparoscopic surgery during
discussion with their physician. We identified three dis-
tinct treatment groups: (1) those who had initial medical
management with methotrexate, (2) those who were eli-
gible for initial medical management but chose surgery
(‘elected’ surgery) and (3) those who initially ‘required’
surgery and did not meet the eligibility criteria for
methotrexate.
For each subject we recorded a comprehensive manage-
ment pathway including any resources used. Any resource
recorded was directly related to the treatment of ectopic
pregnancy and no other condition. These data included
any outpatient appointments, hospital inpatient admis-
sions, general practice (GP) appointments, surgery, ultra-
sound scans, methotrexate administration, haematological
investigation, biochemical investigation and microbio-
logical investigations. Age, BMI, postcode and serum hCG
concentration at diagnosis were also recorded. We calcu-
lated the postcode deprivation using the Scottish Index of
Multiple Deprivation (SIMD) The SIMD ranks small areas
(postcodes) from most deprived – ranked 1 – to least
deprived – ranked 6,505, across all of Scotland in a consist-
ent way (www.scotland.gov.uk).
Data Source
We sourced data using the comprehensive paperless RIE
Pregnancy Support Clinic (PSC) records and database.
In addition, the hospital-wide database TRAK™ database
was interrogated for information about hospital visits
outside PSC. We obtained information regarding GP vis-
its from a combination of the PSC database and TRAK.
The data were cross-referenced with the operating the-
atre record books to ensure all emergency surgery was
accurately identified.
We calculated the costs from the point of view of the
National Health Service (NHS) in the UK. As a result only
costs directly attributable to the NHS were included, ex-
cluding such costs incurred by patient travel and time off
work. We sourced unit costs using Information Service
Division (ISD) Scotland prices (www.isdscotland.org) for
April 2009 to March 2010, specific for the RIE. The ISD
did not have a cost for a serum hCG measurement or
methotrexate and therefore we sourced these costs from
the RIE laboratory price list 2010–11. Laboratory and the-
atre costs were calculated specific to each patient. ISD
present a breakdown of costs for inpatient admissions (in-
cluding laboratory and theatre costs). Consequently, we
subtracted these two costs from the ISD overall inpatient
cost and added our more accurate ‘micro-costing’ to pro-
duce an overall net value. Although ISD has a cost for
nurse-led clinic outpatient appointments, it does not have
a breakdown. As a result, we calculated the cost for a PSC
appointment (nurse-led clinic) using the Personal Social






Age (mean ± SD) 31.5 ± 5.6 31.5 ± 4.8 30.2 ± 6.0
BMI (median/range) 24.5 17.9-41.4 23.9 19.7-29.9 25.2 18.7-43.8
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Health and Social Care 2010’ (www.pssru.ac.uk). This pro-
vided an hourly cost for a staff-nurse and allowed us to ac-
curately add the cost of any resource used during the
consultation (e.g. ultrasound, laboratory investigation,
methotrexate injection). The average time per nurse con-
sultation was calculated at 15 minutes using information
from those conducting the appointments. If the patient
received an ultrasound scan, the appointment time was
estimated at 30 minutes.
All prices used in this study include hospital overhead
costs (e.g. administration, housekeeping, laundry). We
calculated the direct costs for each patient by multiply-
ing the number of each resource used by the unit cost of
the resource. The total cost for each resource was then
added together to give an overall cost for the patient. All
costs were calculated at 2009 values (UK £).
Data Analysis
Cost data are usually right-skewed. Faced with skewed
data one would normally use the median as a measure
of the distribution, along with the range. However, with
a cost analysis it is important to link the summary meas-
ure of cost per patient to the overall budget impact. The
only way to achieve this is to use the mean. Therefore,
we summarised the cost per study group using the
mean, standard deviation, median and range, and to ac-
count for the skewed nature of the data, we calculated
95% confidence intervals for differential costs using the
nonparametric bootstrap method. The 95% percentile
confidence intervals are based on 1000 bootstrap
replications.
We collected postcode and age for all patients with no
missing data. Age showed a normal distribution across
the three groups (Shapiro-Wilk: P >0.05) and as a result
an independent samples student t-test was performed.
Postcode score was not normally distributed (Shapiro-
Wilk: P <0.05) and we used a Chi-Squared analysis to
test whether there was a relationship between postcode
score and management choice for those who were eli-
gible for both treatments. The frequencies were
weighted before the test was performed. We compared
the proportion of failed methotrexate treatment where
the initial hCG concentrations were <1500 IU/l or
≥1500 IU/l using Fisher’s exact test.
All statistical analysis was carried out using IBMW
SPSSW 17. The alpha level was set at α = 0.05 for all stat-
istical tests, equating to a 95% confidence level.
Results
Demographics
During the study period (14 months), 129 patients were
treated for ectopic pregnancy at the Royal Infirmary of
Edinburgh (RIE), Edinburgh, UK. Two patients with non-tubal ectopic pregnancies were excluded after data collec-
tion (a caesarean section scar ectopic and cervical ectopic)
as the management protocols differ in these atypical cases.
Thus, we analysed data from 127 patients: 59 were ineli-
gible for medical management and were managed surgi-
cally, 20 were eligible for medical management but opted
for initial surgical management and 48 were initially mana-
ged medically using systemic methotrexate. All surgery
was performed laparoscopically. There was no significant
difference in age between the medically managed group
and elective surgery group (t = −0.029, df = 66, P > 0.05),
and between the elective surgery and the ‘requiring sur-
gery’ groups (t = 0.859, df = 77, P > 0.05). Statistical analysis
on body mass index (BMI) was not possible due to missing
data (60/129 missing). However, a descriptive comparison
suggested the findings were similar across all three groups
although no definitive conclusion may be drawn (Table 1).
In addition, there were no differences in the postcode
deprivation scores of the women eligible for methotrexate
that opted for initial surgery when compared to those trea-
ted initially with methotrexate.
Outcomes and use of resources
The patients who received methotrexate were monitored
carefully to ensure complete resolution of the ectopic ges-
tation using serial assessment of hCG levels every 4–7 days
until hCG <5 IU/L. We defined treatment failure as those
women in whom the physician responsible for the care
opted for surgical management after methotrexate treat-
ment. This was either due to failure of the hCG to fall,
symptoms such as significant pain or clinical features of
possible tubal rupture or intraperitoneal haemorrhage.
Out of the 48 patients initially medically managed with
methotrexate, 13 required surgery (27%) due to treat-
ment failure. Eight women required additional metho-
trexate (16.7%). Within this group of eight women,
seven received one additional dose of methotrexate, one
of whom then required subsequent surgery, and one
received two additional doses of methotrexate. Seven of
the 48 patients medically managed had an initial serum
hCG level ≥1500 IU/l. Methotrexate therapy failed in
four of these cases (57%) resulting in inpatient admission
and surgery. The patients with initial hCG concentra-
tions <1500 IU/l were less likely to require surgery (Fish-
er’s exact: P < 0.05) for failed methotrexate treatment
(17%). The 48 women had a total length of stay of
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ing treatment failure.
The elective surgery group had a longer length of stay in
hospital on average (1.35 days) compared to the metho-
trexate group (0.68 days) (t = 2.447, df = 66, P < 0.05). The
group requiring surgery, without an option for medical
management, had an even longer average inpatient stay
(1.91 days) (t = 2.497, df = 77, P < 0.05). Two of the 59
women requiring surgical intervention also required an
additional methotrexate injection. These women had evi-
dence of persistent trophoblast on serial hCG testing
instigated because of trophoblast spillage after tubal rup-
ture, or after salpingotomy.
Women initially treated with methotrexate had on
average a far greater number of outpatient PSC
appointments (5.77) compared to those opting for
‘elective surgery’ (0.35) (t = 10.858, df = 105, P < 0.0001)
and those initially ‘requiring surgery’ (0.56) (t = 7.0158,Table 2 Resource use and cost categorised by patient manag
Resource Methotrexate
(U = Use) (n = 48)
(C = Cost(£)) Total Mean SD T
PSC Appointments U 245/32 5.77 3.40 06
(15 min / 30 min) C 1777.75 37.02 21.61
Inpatient care U 33.00 0.68 1.16
(Days) C 17030.36 354.79 603.29 140
Surgery U 13.00 0.27 0.45
(Operations) C 17524.78 365.10 605.40 269
Methotrexate U 57.00 1.19 0.45
(Injections) C 225.15 4.69 1.76
Serum hCG U 255.00 5.31 3.50
(Tests) C 2703.00 56.31 37.12
Ultrasound U 57.00 1.19 1.53
(Scans) C 2816.80 58.66 75.34 1
Haematology U 242.00 5.04 2.01
(Tests) C 719.74 14.97 5.97 1
Biochemistry U 339.00 7.06 3.94
(Tests) C 207.79 4.31 2.40
Microbiology U 75.00 1.56 1.50
(Tests) C 853.75 17.77 17.06 3
A&E U 1.00 0.02 0.14
(Attendances) C 124.00 2.58 17.90 1
GP U 1.00 0.02 0.14
(Appointments) C 53.00 1.10 7.65
Total Cost (£) 43991.47
Cost per patient (£)
mean ± SD 916.49 ±1157.70
median (range) 270.00 (68.88-3948.58)df = 66, P < 0.0001). Patients receiving methotrexate
are required to return to the PSC regularly until hCG
concentrations are <5 IU/l. Patients are monitored at
these appointments and this was reflected in the
increased haematology, clinical biochemistry and in
particular serum hCG measurements (t = 6.549, df =
66, P < 0.0001) and additional ultrasound scans (t =
2.9632, df = 66, P < 0.005) associated with the metho-
trexate group (Table 2). There was no difference in
the number of microbiology specimens requested in
the three management groups.
Cost analysis of treatment
The resource costs for each patient management group are
also shown in Table 2. The mean cost per patient in the ini-
tially medically managed group was £916.49 ± 1157.70
(median = £270.00, range = £68.88 – £3948.58). In the
‘elected’ surgery group, the mean cost per patient wasement group
Elected Surgery Required Surgery
(n = 20) (n = 59)
otal Mean SD Total Mean SD
/01 0.35 0.82 28/05 0.56 1.29
46.00 2.30 4.72 218.50 3.70 8.59
26.93 1.35 0.59 112.60 1.91 0.94
03.89 700.19 305.83 58554.52 992.45 490.03
20.00 1.00 0.00 59.00 1.00 0.00
61.20 1348.06 0.00 79535.54 1348.06 0.00
0.00 0.00 0.00 2.00 0.03 0.18
0.00 0.00 0.00 7.90 0.13 0.72
3.00 0.15 0.37 35.00 0.59 1.59
31.80 1.59 3.89 371.00 6.29 16.83
3.00 0.15 0.50 15.00 0.25 0.63
48.20 7.41 24.17 741.00 12.56 31.23
46.00 2.25 1.08 167.00 2.83 1.53
36.62 6.83 3.21 495.99 8.41 4.55
34.00 1.70 1.92 105.00 1.78 1.51
20.74 1.04 1.17 64.05 1.09 0.92
33.00 1.65 2.01 104.00 1.76 1.69
75.21 18.76 22.82 1182.48 20.04 19.16
1.00 0.05 0.22 0.00 0.00 0.00
24.00 6.20 27.73 0.00 0.00 0.00
1.00 0.05 0.22 7.00 0.12 0.56
53.00 2.65 11.85 371.00 6.29 29.67
41909.81 141568.83
2095.49 ±353.01 2399.47 ±505.10
1922.30 (1738.80-3011.59) 2403.38 (1822.59-4460.59)
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£3011.59). Finally, in the ‘required’ surgery group the mean
cost per patient was £2399.47 ± 505.10 (median = £2403.38,
range = £1822.59 - £4460.59). Of those suitable for either
methotrexate or surgery, methotrexate treatment was
£1179 (CI 819–1550) cheaper than surgery (reflecting
potential savings per patient).
Surgery, followed by inpatient admissions, had the
most substantial impact on cost, accounting for 40% and
39% respectively of the methotrexate group cost, 64%
and 33% respectively for the ‘elected’ surgery group cost
and 56% and 41% respectively of the ‘required’ surgery
group cost. The group that initially required surgery (ie
not eligible for methotrexate) cost significantly more
than the group who were suitable for methotrexate but
elected for surgery (Mann Whitney: U = 347, P < 0.05).
The apparent reason for this increased expense was an
increased inpatient stay post operation (Table 2). These
patients were also more likely to have PSC follow up
appointments for post procedural serial hCG measure-
ments (Fisher’s exact: P < 0.05).
For those medically managed with an initial serum
hCG <1500 IU/l (n = 41) the mean cost per patient
(£813.06 ± 1152.30, median = £169.80, range = £68.88 -
£3948.58) was significantly lower (Mann Whitney: U = 71,
P < 0.05) than those medically managed with an serum
hCG between 1500 and 3000 IU/L (n = 7) (£1522.27 ±
1070.33, median = £1991.10, range = £315.45 - £2923.11).
This difference was accounted for by an increased metho-
trexate failure rate and the need for subsequent surgical
intervention along with inpatient admission. Where
patients had an initial serum hCG between 1500 and
3000 IU/l, the difference in costs between those mana-
ged in the elective surgery group (£2045.16 ± 363.07,
median = £1869.83, range = £1738.80 - £2679.78) and
those initially managed medically (£1522.27 ± 1070.33,
median = £1991.10, range = £315.45-£2923.11) was not
significant (Mann Whitney: U = 22, P > 0.05).
The cost for successful methotrexate treatment was
significantly less (n = 35; mean = £255.67 ±251.75; me-
dian = £159.01, range = £68.88 - £1334.26) than the cost
for failed methotrexate treatment where surgery is
required (n = 13; mean = £2695.61 ± 605.91, median =
£2503.79, range = £1983.50 - £3948.58) (Mann Whitney:
U = 0, P < 0.05). It is clear when comparing elective
and required surgery costs that this difference could
be explained by the added cost of surgery and subse-
quent inpatient admission time. All three groups
showed right-skewed data reflecting a small propor-
tion of patients with notably high costs. This group
of patients reflect complications with treatment or
initial treatment failure and explain the large standard
deviations reported, particularly within the medically
managed group.Discussion
To our knowledge, this is the first cost-analysis compar-
ing medical and surgical management of ectopic preg-
nancy performed in the UK Healthcare system. The
results support the general consensus that medical man-
agement of ectopic pregnancy remains economically
more viable than surgical management for those patients
eligible for both treatment approaches.
Earlier analysis in other health-care settings suggested
that methotrexate is more expensive than laparoscopic
surgery when the initial hCG is >1500 IU/L [2,5]. Mol
et al’s review from 2008 concludes that laparoscopic sur-
gery is the most cost–effective treatment for tubal EP.
However, both economic studies cited [2,3] show cost
savings for medical management in patients with an ini-
tial hCG <1500 IU/L. In the large teaching hospital used
for our study only 7 out of 48 patients managed medic-
ally presented with an initial serum hCG > 1500 IU/L.
Although guidelines do not rule out medical manage-
ment for these patients it is clear other factors and clin-
ician judgement often lead to surgical management.
Although we hypothesised that increased experience
with methotrexate and the increasing use of protocols
developed from evidence-based guidelines [5] would
have reduced the costs of medical management, our
findings also suggest that medical management may not
be less expensive than surgery for patients with initial
serum hCG concentrations between 1500 and 3000 IU/l.
This is due to the occurrence of treatment failure and is
in agreement with Mol et al’s 1999 metanalysis of older
economic evaluations of managements for ectopic preg-
nancy [2]. Although the different healthcare systems
may have different costs it is likely that cost differentials
are similar and that our findings are applicable to other
health care settings.
One of the main strengths of our study is that we per-
formed a comprehensive detailed retrospective analysis
of all patients managed in a specified time period. There
were no missing data values and all direct UK health
care costs were taken into account. The cost of post-
treatment complications and secondary treatment were
included, making this study comprehensive and realistic
in reflecting the cost to UK health services. We had
similar age, BMI and deprivation index baseline charac-
teristics for each treatment group. A further strength
was that, where possible, we used national hospital-cost
databases (ISD Scotland, PSSRU) allowing hospitals
across the UK to relate to the findings. Any costs not
sourced from these databases were calculated with ad-
vice from a health economist.
On the other hand, the study has some limitations.
We only took into account direct UK healthcare costs.
Indirect costs, such as travel expenses and time off work,
are undoubtedly important. In addition, we did not
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we predict that the costs may not be less than successful
methotrexate treatment. Furthermore, we decided to
focus solely on costs in this study but it is important to
acknowledge that health benefits and quality of life are
also extremely relevant. For example, if women in the
surgery group have a better quality of life than the
methotrexate group, this may be a more cost effective
option overall.
Conclusions
The clear message from this study is that it is the cost of
treatment failure and subsequent surgery that makes
methotrexate less cost-effective in women with hCG
concentrations of >1500 IU/L. This finding is still the
same after over 10 years of increasing experience and
more standardised treatment. This means that, rather
than minor monitoring or follow-up changes, there are
two important areas for research to improve the cost-
effectiveness of medical management of ectopic preg-
nancy. The first is the identification of clinical features
or biomarkers predictive of methotrexate success and
the second is the use of additional medical treatments or
novel adjuncts that reduce treatment failures.
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